(Q50198506)

English

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study

scientific article published on 18 January 2018

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study (English)

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

type 2 diabetes

0 references

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

David G Warnock

11

object named as

David G Warnock

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

4

object named as

Glenn M Chertow

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Christoph Wanner

10

object named as

Christoph Wanner

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Geoffrey A. Block

3

object named as

Geoffrey A Block

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

author name string

Melanie P Chin

1

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

George L Bakris

2

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Angie Goldsberry

5

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Lesley A Inker

6

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Hiddo J L Heerspink

7

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Megan O'Grady

8

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Pablo E Pergola

9

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Colin J Meyer

12

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

publication date

18 January 2018

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

American Journal of Nephrology

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

47

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

1

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

40-47

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Avosentan for overt diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

22 June 2018

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5841134

14 August 2018

Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD

1 reference

https://pubmed.ncbi.nlm.nih.gov/29402767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/29402767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1159/000486398

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5841134

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50198506&oldid=2255067383"